Frontera Therapeutics files for HKEX listing; rAAV gene therapy company focused on ophthalmology and cardiovascular diseases with six candidates

NewTimeSpace News: On 28 August 2026, Frontera Therapeutics filed a listing application with HKEX. Incorporated in 2019, the Company is a clinical-stage gene therapy company dedicated to the in-house development of recombinant adeno-associated virus (rAAV) gene therapies, with a pipeline particularly focused on ophthalmic and cardiovascular diseases.

As of the last practicable date, the Company's pipeline comprises six in-house developed rAAV gene therapy candidates, including two core products — FT-002, a candidate under investigation for the treatment of X-linked retinitis pigmentosa (XLRP), and FT-003, a candidate under investigation via intravitreal injection for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME); one key product, FT-001, a gene therapy candidate for inherited retinal disease (IRD) caused by biallelic mutations in the RPE65 gene (RPE65-related IRD); and three other gene therapy candidates at preclinical and early stages for ophthalmic and cardiovascular diseases.

In terms of intellectual property, as of the last practicable date, the Company's patent portfolio comprises one Japanese patent and 29 patent applications, including seven Patent Cooperation Treaty (PCT) applications, seven US applications, five China applications (including one Hong Kong application), two Canadian applications, three European applications, two Japanese applications, two Australian applications and one Korean application, mainly covering compositions, methods and uses related to its drug candidates and technology platforms.

With respect to the core products' patents, FT-002 has five patent applications in China, the United States, Europe and Japan, with one US application receiving a notice of allowance in May 2026; FT-003 obtained one patent in Japan in April 2026 and has seven patent applications in China (including Hong Kong), the United States, Europe, Canada and Australia, with its US application receiving a notice of allowance in June 2026. The Company has engaged IP counsel to oversee the comprehensive planning and development of its IP portfolio; during the track record period and up to the last practicable date, the Company has not received any material concerns or inquiries from relevant authorities.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.